Our long-term goal is to develop potent agents for prevention and treatment of anthrax and methicillinresistant S. aureus (MRSA) by engineering phage endolysins. PlyG, a lysin of 25 kDa molecular weight encoded by gamma phage. PlyG contains a T7 lysozyme-like catalytic domain capable of hydrolyzing B. anthracis cell wall peptidoglycan, resulting in bacterial cell lysis, attached to a -75 amino acid C- terminal domain. The C-terminal domain is a dimeric carbohydrate recognition module that targets the enzyme specifically to vegetative B. anthracis cells and germinating spores. We hypothesize that full- length PlyG exists in a monomeric inactive state stabilized by specific contacts between the N- and C-terminal domains, and that binding of the C-terminal (regulatory) domain to carbohydrates unique to the B. anthracis cell wall releases the autoinhibitory interaction and promotes formation of the fully active, dimeric PlyG enzyme. Phage endolytic enzymes like PlyG have the potential to serve as novel and powerful antibiotic agents, termed 'enzybiotics'. We broadened this approach to include MRSA by assembling an enzybiotic from other phage lysins with specific S. aureus activity. ClyS is a chimeric protein containing an N-terminal catalytic domain and a C-terminal cell wall targeting domain. The N-terminal catalytic domain is an endopeptidase of 184 amino acids and the C-terminal cell wall targeting domain is 94 residues.
In aim 1, we will determine the NMR structure of full-length (inactive) PlyG to reveal the molecular basis of lysin autoinhibition for this class of antibacterial enzymes, and solve structures of the ClyS lysin and its component domains.
In Aim 2, the basis for specific anthrax and MRSA targeting will be elucidated using NMR to monitor interactions between cell wall components and the PlyG and ClyS binding domains.
Aim 3 will exploit this structural knowledge to engineer isoforms of PlyG and ClyS with enhanced stability in vivo. Because the bacterium must alter the basic construction of the cell wall to evade an enzybiotic, the probability that PlyG- and ClyS- resistant strains will emerge is low. These studies will provide important mechanistic insights into a novel class of antibacterial compounds moving toward clinical application.

Public Health Relevance

Methicillin-resistant S. aureus (MRSA) and anthrax pose serious threats to public health. The enzyme PlyG possesses unique anti- anthrax activity that can be exploited for treating infection and detecting germinating spores. A similar enzyme, ClyS, was engineered to kill MRSA strains. The proposed studies will reveal at a molecular level the manner in which each protein recognizes a specific type of bacteria and kills it by dismantling the cell wall, and enable the development of improved PlyG and ClyS formulations for treatment of bacterial infections in human patients.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
United States
Zip Code
Sharma, Preeti; Wang, Ningyan; Kranz, David M (2014) Soluble T cell receptor V? domains engineered for high-affinity binding to staphylococcal or streptococcal superantigens. Toxins (Basel) 6:556-74
Schuld, Nathan J; Vervacke, Jeffrey S; Lorimer, Ellen L et al. (2014) The chaperone protein SmgGDS interacts with small GTPases entering the prenylation pathway by recognizing the last amino acid in the CAAX motif. J Biol Chem 289:6862-76
Becker, Russell E N; Berube, Bryan J; Sampedro, Georgia R et al. (2014) Tissue-specific patterning of host innate immune responses by Staphylococcus aureus ?-toxin. J Innate Immun 6:619-31
Pensinger, Daniel A; Aliota, Matthew T; Schaenzer, Adam J et al. (2014) Selective pharmacologic inhibition of a PASTA kinase increases Listeria monocytogenes susceptibility to ?-lactam antibiotics. Antimicrob Agents Chemother 58:4486-94
Schiano, Chelsea A; Koo, Jovanka T; Schipma, Matthew J et al. (2014) Genome-wide analysis of small RNAs expressed by Yersinia pestis identifies a regulator of the Yop-Ysc type III secretion system. J Bacteriol 196:1659-70
Stach, Christopher S; Herrera, Alfa; Schlievert, Patrick M (2014) Staphylococcal superantigens interact with multiple host receptors to cause serious diseases. Immunol Res 59:177-81
Lifshitz, Ziv; Burstein, David; Schwartz, Kierstyn et al. (2014) Identification of novel Coxiella burnetii Icm/Dot effectors and genetic analysis of their involvement in modulating a mitogen-activated protein kinase pathway. Infect Immun 82:3740-52
Merriman, Joseph A; Nemeth, Kimberly A; Schlievert, Patrick M (2014) Novel antimicrobial peptides that inhibit gram positive bacterial exotoxin synthesis. PLoS One 9:e95661
Schneewind, Olaf; Missiakas, Dominique (2014) Genetic manipulation of Staphylococcus aureus. Curr Protoc Microbiol 32:Unit 9C.3.
Wang, Ya-Ting; Missiakas, Dominique; Schneewind, Olaf (2014) GneZ, a UDP-GlcNAc 2-epimerase, is required for S-layer assembly and vegetative growth of Bacillus anthracis. J Bacteriol 196:2969-78

Showing the most recent 10 out of 420 publications